Molecular pathological epidemiology
Molecular pathological epidemiology (MPE, also molecular pathologic epidemiology) is a
Disease process
Data from
Methodology
In MPE, investigators dissect interrelationships between exposures (e.g., environmental, dietary, lifestyle and genetic factors); alterations in cellular or extracellular molecules (disease molecular signatures); and disease evolution and progression.
MPE research enables identification of a new biomarker for potential clinical utility, using large-scale population-based data (e.g., PIK3CA mutation in colorectal cancer to select patients for aspirin therapy).[1] The MPE approach can be used following a genome-wide association study (GWAS), termed "GWAS-MPE approach".[4] Detailed disease endpoint phenotyping can be conducted by means of molecular pathology or surrogate histopathology or immunohistochemistry analysis of diseased tissues and cells within GWAS.[5][6]
As an alternative approach, potential risk variants identified by GWAS can be examined in combination with molecular pathology analysis on diseased tissues.[7][8][9][10] This GWAS-MPE approach can give not only more precise effect estimates, even larger effects, for specific molecular subtypes of the disease, but also insights into pathogenesis by linking genetic variants to molecular pathologic signatures of disease.[4] Since molecular diagnostics is becoming routine clinical practice, molecular pathology data can aid epidemiologic research.[citation needed]
History
MPE began as analysis of risk factors (e.g., smoking) and molecular pathological findings (e.g., KRAS G12C oncogene mutations in lung carcinoma).[citation needed]
Studies to examine the relationship between an exposure and molecular pathological signatures of disease (particularly, cancer) became increasingly common throughout the 1990s and early 2000s.[11]
The use of molecular pathology in epidemiology lacked standardized methodologies and guidelines as well as interdisciplinary experts and training programs.[12] MPE research required a new conceptual framework and methodologies (epidemiological method) because MPE examines heterogeneity in an outcome variable.[13]
The term "molecular pathological epidemiology" was used by Shuji Ogino and Meir Stampfer in 2010.[14] Specific principles of MPE developed following 2010. The MPE paradigm is in widespread use globally,[15][16][17][18][19][20][21][22][23][24][25][excessive citations] and has been a subject of international conferences.[26][27][28] The International Molecular Pathological Epidemiology (MPE) Meeting Series, which was established in 2013, has been open to the research community around the world, and five meetings were held through 2021.[29][30][31][32]
See also
References
- ^ PMID 23792451.
- ^ PMID 23307060.
- PMID 22845482.
- ^ PMID 21036793.
- PMID 23535649.
- PMID 23535733.
- PMID 17630503.
- PMID 20124488.
- PMID 23104301.
- PMID 24317174.
- PMID 12239192.
- PMID 20332257.
- PMID 22935516.
- PMID 20208016.
- PMID 21559209.
- PMID 23034130.
- PMID 22522846.
- PMID 22481034.
- PMID 23014527.
- PMID 23230187.
- PMID 23127612.
- PMID 23801749.
- S2CID 3463193.
- PMID 24614287.
- PMID 24876728.
- PMID 24105654.
- PMID 25277796.
- PMID 25956270.
- ^ "The Ogino MPE lab". Dana-Farber Cancer Institute. Archived from the original on 2019-05-15. Retrieved 2020-04-07.
- PMID 28097472.
- ^ Campbell et al. Cancer Causes Cont 2019
- ^ "Home". mpemeeting.org.
Further reading
- Gao C (2016). "Molecular pathological epidemiology in diabetes mellitus and risk of hepatocellular carcinoma". World Journal of Hepatology. 8 (27): 1119–1127. PMID 27721917.
- Rescigno T, Micolucci L, Tecce MF, Capasso A (2017). "Bioactive Nutrients and Nutrigenomics in Age-Related Diseases". Molecules (Basel, Switzerland). 22 (1): 105. PMID 28075340.
- Patil H, Saxena SG, Barrow CJ, Kanwar JR, Kapat A, Kanwar RK (2017). "Chasing the personalized medicine dream through biomarker validation in colorectal cancer". Drug Discovery Today. 22 (1): 111–119. PMID 27693431.
